News / Taiwan / economic_daily
Evercyte Reports Q3 EPS of NT$3.42, Driven by Cell Therapy Expansion
Health Technology · Biotechnology · economic_daily · 2026-11-04
6712
Evercyte announced steady growth for the first nine months of the year, supported by its expanding cell therapy and CDMO business segments.
What Happened
Financial Results: Evercyte reported a net profit of NT$344 million for the first nine months, an 11.2% increase year-over-year, resulting in an EPS of NT$3.42. While quarterly figures were impacted by dividend adjustments, the company noted that underlying profitability remains stronger than the previous year.
Business Operations: The company continues to prioritize its core cell therapy services, cell preparation, and Contract Development and Manufacturing Organization (CDMO) operations. These segments remain central to the company's ongoing business strategy and revenue generation.
Clinical Progress: Evercyte is actively advancing its CAR-T new drug development, with multiple clinical trials currently underway for various types of cancer. This commitment to R&D is expected to play a key role in the company's long-term growth trajectory.
Market Outlook: Analysts maintain a positive outlook for the company, anticipating sustained growth into next year. The expansion of cell therapy applications and the scaling of CDMO services are expected to be the primary drivers of future performance.